Morgan Stanley
AUTL

Morgan Stanley’s Autolus Therapeutics AUTL Stock Holding History

Morgan Stanley’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Buy
1,260,832
+319,009
+34% +$500K ﹤0.01% 4848
2026
Q1 		$1.3M Sell
941,823
-455,428
-33% -$692K ﹤0.01% 5013
2025
Q4 		$2.78M Buy
1,397,251
+183,478
+15% +$282K ﹤0.01% 4584
2025
Q3 		$1.98M Buy
1,213,773
+751,167
+162% +$1.47M ﹤0.01% 4798
2025
Q2 		$1.05M Buy
462,606
+153,030
+49% +$253K ﹤0.01% 5062
2025
Q1 		$480K Sell
309,576
-243,558
-44% -$494K ﹤0.01% 5344
2024
Q4 		$1.3M Sell
553,134
-1,264,821
-70% -$4.28M ﹤0.01% 4951
2024
Q3 		$6.6M Sell
1,817,955
-1,086,888
-37% -$4.33M ﹤0.01% 3743
2024
Q2 		$10.1M Buy
2,904,843
+2,214,370
+321% +$9.56M ﹤0.01% 3316
2024
Q1 		$4.41M Buy
690,473
+609,104
+749% +$3.8M ﹤0.01% 4014
2023
Q4 		$524K Sell
81,369
-70,573
-46% -$269K ﹤0.01% 5267
2023
Q3 		$354K Sell
151,942
-8,372
-5% -$23.9K ﹤0.01% 5319
2023
Q2 		$382K Buy
160,314
+103,917
+184% +$247K ﹤0.01% 5352
2023
Q1 		$104K Sell
56,397
-38,865
-41% -$76K ﹤0.01% 5987
2022
Q4 		$181K Buy
95,262
+51,312
+117% +$130K ﹤0.01% 5706
2022
Q3 		$94K Sell
43,950
-24,433
-36% -$72.4K ﹤0.01% 6109
2022
Q2 		$194K Sell
68,383
-106,876
-61% -$325K ﹤0.01% 5918
2022
Q1 		$731K Buy
175,259
+19,319
+12% +$81.2K ﹤0.01% 5182
2021
Q4 		$809K Sell
155,940
-37,105
-19% -$223K ﹤0.01% 5233
2021
Q3 		$1.26M Sell
193,045
-85,219
-31% -$538K ﹤0.01% 4892
2021
Q2 		$1.85M Buy
278,264
+137,038
+97% +$851K ﹤0.01% 4692
2021
Q1 		$810K Buy
141,226
+12,017
+9% +$89K ﹤0.01% 4861
2020
Q4 		$1.16M Buy
129,209
+93,519
+262% +$997K ﹤0.01% 4581
2020
Q3 		$415K Sell
35,690
-54,888
-61% -$796K ﹤0.01% 4728
2020
Q2 		$1.45M Buy
+90,578
New +$1M ﹤0.01% 3878
2019
Q2 		– Sell
-27
Closed -$1K – 6636
2019
Q1 		$1K Buy
+27
New +$768 ﹤0.01% 6498

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley's AUTL Position: Q2 2026 in Review

Morgan Stanley increased its Autolus Therapeutics (AUTL) stake by 34% in Q2 2026, buying an estimated $500K and bringing the position to 1,260,832 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #4848.

Morgan Stanley first reported a position in AUTL in Q1 2019 and has held it in 26 quarters since. The position peaked at $10.1M in Q2 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Morgan Stanley held 1,260,832 shares of Autolus Therapeutics worth $2.02M as of Q2 2026.
  • Morgan Stanley bought 319,009 Autolus Therapeutics shares in Q2 2026, an estimated $500K.
  • Autolus Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4848 holding.
  • Morgan Stanley first reported a position in Autolus Therapeutics in Q1 2019 and has held it in 26 quarters since.
  • Morgan Stanley's Autolus Therapeutics position peaked at $10.1M in Q2 2024.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.